LRMR — Larimar Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $190.16m
- $32.64m
Annual income statement for Larimar Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 42.8 | 50.5 | 36.5 | 41.8 | 90.9 |
| Operating Profit | -42.8 | -50.5 | -36.5 | -41.8 | -90.9 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -42.5 | -50.6 | -35.4 | -36.9 | -80.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -42.5 | -50.6 | -35.4 | -36.9 | -80.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -42.5 | -50.6 | -35.4 | -36.9 | -80.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -42.5 | -50.6 | -35.4 | -36.9 | -80.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.57 | -2.95 | -1.37 | -0.842 | -1.32 |